Lactoferrin as potential preventative and adjunct treatment for COVID-19

Int J Antimicrob Agents. 2020 Sep;56(3):106118. doi: 10.1016/j.ijantimicag.2020.106118. Epub 2020 Jul 30.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is rapidly advancing across the globe despite drastic public and personal health measures. Antivirals and nutritional supplements have been proposed as potentially useful against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes COVID-19, but few have been clinically established. Lactoferrin (Lf) is a naturally occurring, non-toxic glycoprotein that is orally available as a nutritional supplement and has established in vitro antiviral efficacy against a wide range of viruses, including SARS-CoV, a closely related coronavirus to SARS-CoV-2. Furthermore, Lf possesses unique immunomodulatory and anti-inflammatory effects that may be especially relevant to the pathophysiology of severe COVID-19 cases. Here we review the underlying biological mechanisms of Lf as an antiviral and immune regulator, and propose its unique potential as a preventative and adjunct treatment for COVID-19. We hope that further research and development of Lf nutritional supplementation would establish its role for COVID-19.

Keywords: Antiviral; COVID-19; Lactoferrin; SARS-CoV-2; Viral prophylaxis.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / virology
  • Heparan Sulfate Proteoglycans / antagonists & inhibitors
  • Heparan Sulfate Proteoglycans / metabolism
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferons / agonists
  • Interferons / biosynthesis
  • Lactoferrin / therapeutic use*
  • Pandemics* / prevention & control
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Severity of Illness Index
  • Virus Internalization / drug effects
  • Virus Replication / drug effects

Substances

  • Anti-Inflammatory Agents
  • Antiviral Agents
  • Heparan Sulfate Proteoglycans
  • Immunologic Factors
  • Interferons
  • Lactoferrin